HOOKIPA Pharma Inc. (HOOK)
| Market Cap | 14.80M |
| Revenue (ttm) | 43.95M |
| Net Income (ttm) | -43.50M |
| Shares Out | 12.54M |
| EPS (ttm) | -3.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35,385 |
| Open | 1.190 |
| Previous Close | 1.200 |
| Day's Range | 1.170 - 1.230 |
| 52-Week Range | 1.110 - 10.500 |
| Beta | 0.70 |
| Analysts | Buy |
| Price Target | 10.67 (+804.24%) |
| Earnings Date | May 8, 2025 |
About HOOK
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company’s immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head an... [Read more]
Financial Performance
In 2024, HOOKIPA Pharma's revenue was $43.95 million, an increase of 118.32% compared to the previous year's $20.13 million. Losses were -$43.50 million, -46.67% less than in 2023.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for HOOK stock is "Buy." The 12-month stock price forecast is $10.67, which is an increase of 804.24% from the latest price.
News
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIO...
Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
HOOKIPA Pharma Inc - FORM 8 (OPD)
NEW YORK and VIENNA, Austria, Jan. 08, 2025 (GLOBE NEWSWIRE) -- FORM 8 (OPD) PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER Rules 8.1 and 8.2 of the Takeover Code (the “Code”) 1. KEY...
HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements
NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage biopharmaceutical company developing next generation immu...
HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker
Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell respo...
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024 Society of Immunotherapy of Cancer (SITC)...
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
Study done in collaboration with Memorial Sloan Kettering and led by Dr. Winston Wong, Head and Neck Oncologist and Dr. Alan Ho, Chief of the Head and Neck Oncology Service
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024 Preclinical proof-of-concept package to be presented at Industry Summit on RAS being hel...
Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating HOOKIPA Pharma Inc. (NASDAQ: HOOK) on behalf of the company's shareholders. Since May 2024, shares of HOOKIPA's stock ...
HOOKIPA Pharma Announces Board of Directors Changes
NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (“HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its proprietary ...
HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
NEW YORK and VIENNA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a company developing a new class of immunotherapeutics based on its proprietary are...
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 “AVALON-1” study with eseba-vec in Q4 2024
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (”HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its proprietary ...
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
NEW YORK and VIENNA, July 08, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platfor...
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
NEW YORK and VIENNA, July 01, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform,...
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
NEW YORK and VIENNA, June 04, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platfor...
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
NEW YORK and VIENNA, May 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA or the Company), a company developing a new class of immunotherapeutics based on its proprietary arenav...
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
NEW YORK and VIENNA, May 23, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform...
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
NEW YORK and VIENNA, May 09, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform...
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
NEW YORK and VIENNA, Austria, April 25, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA or the Company), a company developing a new class of immunotherapeutics based on its proprie...
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavir...
Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts
Hookipa Pharma is conducting a call on 04/25/24 to share lead asset HB-200's pivotal trial design. A Phase 2a clinical update is due in 2Q'24. The company's shares closed at $0.733, with a valuation ...
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and VIENNA, Austria, April 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavir...